Data sharing and intellectual property in a genomic epidemiology network: Policies for large-scale research collaboration

Bulletin of the World Health Organization

Volumn 84, Issue 5, 2006, Pages 382-387

  Chokshi, Dave A ^a   Parker, Michael ^b   Kwiatkowski, Dominic P ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DATA MANAGEMENT; DISEASE CONTROL; EPIDEMIOLOGY; GENOMICS; INTELLECTUAL PROPERTY RIGHTS; RESEARCH PROGRAM;

ACCESS TO INFORMATION; ARTICLE; DEVELOPING COUNTRY; DIAGNOSTIC ACCURACY; DRUG INDUSTRY; FUNDING; GENETIC EPIDEMIOLOGY; GENOTYPE; HEALTH CARE POLICY; INFORMATION DISSEMINATION; INFORMATION RETRIEVAL; MALARIA; MARKETING; MEDICAL RESEARCH; MOLECULAR EVOLUTION; PATENT; PEER REVIEW; PREVENTION;

ACCESS TO INFORMATION; EPIDEMIOLOGIC STUDIES; HUMANS; INTELLECTUAL PROPERTY; INTERNATIONAL COOPERATION; MALARIA; POLICY MAKING;

EID: 33646487329     PISSN: 00429686     EISSN: 15640604     Source Type: Journal    
DOI: 10.2471/BLT.06.029843     Document Type: Article

References (32)

1. Altshuler D, Brooks LD, Chakravarti A, Collins FS, Daly MJ, Donnelly P. A haplotype map of the human genome. Nature 2005;437:1299-320.
2. Ghedin E, Sengamalay NA, Shumway M, Zaborsky J, Feldblyum T, Subbu V, et al. Large-scale sequencing of human influenza reveals the dynamic nature of viral genome evolution. Nature 2005;437:1162-6.
3. Mu J, Awadalla P, Duan J, McGee KM, Joy DA, McVean GA, et al. Recombination hotspots and population structure in Plasmodium falciparum. PLoS Biol 2005;3:e335.
4. Risch NJ. Searching for genetic determinants in the new millennium. Nature 2000;405:847-56.
5. Varmus H, Klausner R, Zerhouni E, Acharya T, Daar AS, Singer PA. Public health. Grand Challenges in Global Health. Science 2003;302:398-9.
6. Chokshi DA, Kwiatkowski DP. Ethical Challenges of Genomic Epidemiology in Developing Countries. Genomics, Society and Policy 2005;1:1-15.
7. Kapczynski A, Chaifetz S, Katz Z, Benkler Y. Addressing Global Health Inequities: An Open Licensing Approach for University Innovations. Berkeley Technology Law Journal 2005;20:1031-114.
8. T1DGC Publication and Presentations Policies. Winston-Salem, Type 1 Diabetes Genetics Consortium, 2004.
9. Sharing Data from Large-scale Biological Research Projects: A System of Tripartite Responsibility. London: The Wellcome Trust; 2003.
10. The ethics of patenting DNA. London: Nuffield Council on Bioethics; 2002.
11. Data release and access policy. London: Wellcome Trust Case Control Consortium, 2006.
12. Eisenberg RS. Science and the law. Patent swords and shields. Science 2003;299:1018-9.
13. Miller LH, Mason SJ, Clyde DF, McGinniss MH. The resistance factor to Plasmodium vivax in blacks. The Duffy-blood-group genotype, FyFy. N Engl J Med 1976;295:302-4.
14. Chitnis CE, Miller LH. Identification of the erythrocyte binding domains of Plasmodium vivax and Plasmodium knowlesi proteins involved in erythrocyte invasion. J Exp Med 1994;180:497-506.
15. Arevalo-Herrera M, Herrera S. Plasmodium vivax malaria vaccine development. Mol Immunol 2001;38:443-55.
16. Yazdani SS, Shakri AR, Mukherjee P, Baniwal SK, Chitnis CE. Evaluation of immune responses elicited in mice against a recombinant malaria vaccine based on Plasmodium vivax Duffy binding protein. Vaccine 2004;22:3727-37.
17. Ashley-Koch A, Yang Q, Olney RS. Sickle haemoglobin (HbS) allele and sickle cell disease: a HuGE review. Am J Epidemiol 2000;151:839-45.
18. Modiano D, Luoni G, Sirima BS, Simpore J, Verra F, Konate A, et al. Haemoglobin C protects against clinical Plasmodium falciparum malaria. Nature 2001;414:305-8.
19. Williams TN, Mwangi TW, Roberts DJ, Alexander ND, Weatherall DJ, Wambua S, et al. An immune basis for malaria protection by the sickle cell trait. PLoS Med 2005;2:e128.
20. Fairhurst RM, Baruch DI, Brittain NJ, Ostera GR, Wallach JS, Hoang HL, et al. Abnormal display of PfEMP-1 on erythrocytes carrying haemoglobin C may protect against malaria. Nature 2005;435:1117-21.
21. Statement on the principled conduct of genetics research of the Human Genome Organisation. Statement approved by HUGO Council on 21 March 1996, Heidelberg, Germany. Law Hum Genome Rev 2000;12:253-5.
22. Global Access Strategy and IP Management Policy. Seattle: Gates Foundation; 2005.
23. Trouiller P, Olliaro P, Torreele E, Orbinski J, Laing R, Ford N. Drug development for neglected diseases: a deficient market and a public-health policy failure. Lancet 2002;359:2188-94.
24. Merz JF. Intellectual Property and Product Development Public/Private Partnerships. Geneva: World Health Organization Commission on Intellectual Property Rights, Innovation and Public Health; 2005.
25. Widdus R, White K. Combating Diseases Associated with Poverty: Financing Strategies for Product Development and the Potential Role of Public-Private Partnerships. Geneva: Initiative on Public-Private Partnerships for Health; 2004.
26. Moran M. A breakthrough in R&D for neglected diseases: new ways to get the drugs we need. PLoS Med 2005;2:e302.
27. Nwaka S, Ridley RG. Virtual drug discovery and development for neglected diseases through public-private partnerships. Nat Rev Drug Discov 2003; 2:919-28.
28. Gardner C, Garner C. Technology Licensing to Non-traditional Partners: Non-Profit Health Product Development Organizations for Better Global Health. Oxford: Centre for the Management of Intellectual Property in Health; 2004.
29. Chokshi DA. Universities should foster neglected-disease work. Nature 2005;435:143.
30. Daviss B. Malaria, science, and social responsibility. The Scientist 2005:42.
31. Salicrup LA, Rohrbaugh ML. Partnerships in technology transfer. An innovative program to enhance biomedical research and global health. Int Microbiol 2005;8:1-3.
32. Webber D, Kremer M. Perspectives on stimulating industrial research and development for neglected infectious diseases. Bull World Health Organ 2001;79: 735-41.